Threonine

Threonine

SCHEMBL562233

CC(O)C(N)C(=O)O.c1ccc2c(c1)C2

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.42
SLC1A2 P43004 7/20 0.41
SLC1A3 P43003 6/20 0.41
SLC1A1 P43005 6/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
DPP7 Q9UHL4 2/20 0.41
DPP4 P27487 1/20 0.41
SLC7A5 Q01650 1/20 0.40
TARS1 P26639 1/20 0.38
LMNA P02545 2/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Threonine SCHEMBL567434 1.00 HTR2A (0.42) HTR2ASLC1A2SLC1A3SLC1A1DPP8
Threonine SCHEMBL10663811 1.00 HTR2A (0.42) HTR2ASLC1A2SLC1A3SLC1A1DPP8
Threonine SCHEMBL7322815 0.88 SLC1A3 (0.37) HTR2ASLC1A2SLC1A3SLC1A1DPP8
Alanine SCHEMBL16899299 0.82 HTR2A (0.46) HTR2ASLC1A2SLC1A3SLC1A1DPP8
Threonine SCHEMBL2895194 0.82 SLC7A5 (0.57) SLC1A2SLC1A3SLC1A1SLC7A5TARS1
Benzoic Acid SCHEMBL28091621 0.79 TSHR (0.54) SLC1A2SLC1A3SLC1A1SLC7A5LMNA
Threonine SCHEMBL3448821 0.78 AKR1B1 (0.43) SLC1A2SLC1A3SLC1A1SLC7A5TARS1
Threonine SCHEMBL27615994 0.78 SLC7A5 (0.52) SLC1A2SLC1A3SLC1A1SLC7A5TARS1
Threonine SCHEMBL92730 0.77
Threonine SCHEMBL18050155 0.77 SLC7A5 (0.63) SLC1A2SLC1A3SLC1A1SLC7A5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116655730-A Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases 雅斯娜 2023-08-29 CN claimed
CN-114805487-A Polypeptide compound and application thereof 成都诺和晟泰生物科技有限公司 2022-07-29 CN claimed
CN-113045625-A Polypeptide as growth hormone secretagogue receptor agonist and application thereof 成都诺和晟泰生物科技有限公司 2021-06-29 CN claimed
EP-2722051-A1 Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus Seattle Genetics, Inc. (US) 2014-04-23 EP claimed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 US claimed
EP-1917020-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS Seattle Genetics, Inc. (US) 2008-05-07 EP claimed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 WO claimed
EP-0709373-B1 PYRROLIDINE DERIVATIVE ZAIDAN HOJIN BISEIBUTSU (JP) 2001-10-17 EP claimed
US-5753619-A CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) 1998-05-19 US claimed
EP-0714909-A1 Composition for prophylaxis or treatment of pulmonary circulatory diseases Takeda Chemical Industries, Ltd. (JP) 1996-06-05 EP claimed
EP-0272671-B1 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD (CH) 1994-03-16 EP claimed
US-5055451-A Prevent tissue damage SYNTEX INC. (US) 1991-10-08 US claimed
EP-0272671-A2 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD. (CH) 1988-06-29 EP claimed
US-4483807-A Process for producing a slow release composite JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) 1984-11-20 US claimed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US claimed
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2025-12-02 US disclosed
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ZEALAND PHARMA A/S (DK) 2024-09-03 US disclosed
US-4370312-A HAPTENS, TRACERS, ANTIBODIES AND STARTING MATERIALS FOR INTERFERONS Dr. Karl Thomae Gesellshaft mit beschrankter Haftung (DE) 1983-01-25 US disclosed
US-4127532-A ANALGESIC VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY 1978-11-28 US disclosed
US-3936469-A Process for preparing N-carboxylic anhydrides of amino acids KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ITGB7, ITGB4, ITGA4 HTR2A 4856/4885SLC1A2 4069/4885SLC1A3 3008/4885
US-12486302-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 HTR2A 410/4885SLC1A2 731/4885SLC1A3 805/4885
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus MMAB, DNPEP, MARCKS HTR2A 4705/4885SLC1A2 571/4885SLC1A3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.